IL105064A - METHOD TO INHIBIT THE CONVERSION OF HUMAN FACTOR X TO HUMAN FACTOR Xa BY MEANS OF A REAGENT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID REAGENT - Google Patents

METHOD TO INHIBIT THE CONVERSION OF HUMAN FACTOR X TO HUMAN FACTOR Xa BY MEANS OF A REAGENT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID REAGENT

Info

Publication number
IL105064A
IL105064A IL105064A IL10506493A IL105064A IL 105064 A IL105064 A IL 105064A IL 105064 A IL105064 A IL 105064A IL 10506493 A IL10506493 A IL 10506493A IL 105064 A IL105064 A IL 105064A
Authority
IL
Israel
Prior art keywords
reagent
factor
human factor
conversion
inhibit
Prior art date
Application number
IL105064A
Other languages
English (en)
Other versions
IL105064A0 (en
Original Assignee
Cor Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics filed Critical Cor Therapeutics
Publication of IL105064A0 publication Critical patent/IL105064A0/xx
Publication of IL105064A publication Critical patent/IL105064A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/827—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL105064A 1992-03-20 1993-03-16 METHOD TO INHIBIT THE CONVERSION OF HUMAN FACTOR X TO HUMAN FACTOR Xa BY MEANS OF A REAGENT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID REAGENT IL105064A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85410992A 1992-03-20 1992-03-20

Publications (2)

Publication Number Publication Date
IL105064A0 IL105064A0 (en) 1993-07-08
IL105064A true IL105064A (en) 1997-04-15

Family

ID=25317754

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105064A IL105064A (en) 1992-03-20 1993-03-16 METHOD TO INHIBIT THE CONVERSION OF HUMAN FACTOR X TO HUMAN FACTOR Xa BY MEANS OF A REAGENT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID REAGENT

Country Status (9)

Country Link
US (3) US6117836A (ja)
EP (1) EP0631501B1 (ja)
JP (1) JPH07507769A (ja)
AT (1) ATE195873T1 (ja)
AU (1) AU681074B2 (ja)
CA (1) CA2132518A1 (ja)
DE (1) DE69329333D1 (ja)
IL (1) IL105064A (ja)
WO (1) WO1993018782A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
CA2145881C (en) 1992-10-02 2000-12-19 Richard Smith Anti-inflammatory, tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides
SE507737C2 (sv) * 1996-11-08 1998-07-06 Golvabia Ab Anordning för sammanfogning av golvbeläggningsmaterial
SG185263A1 (en) 2007-09-28 2012-11-29 Portola Pharm Inc Antidotes for factor xa inhibitors and methods of using the same
US8268783B2 (en) * 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
DK2436765T3 (da) 2007-10-09 2014-01-13 Chemo Sero Therapeut Res Inst Rekombinant faktor X uden glycosylering og fremgangsmåde til fremstilling deraf
KR101673195B1 (ko) * 2013-11-18 2016-11-07 한국생명공학연구원 구멍장이 버섯 유래의 시알산 결합 특이적인 재조합 렉틴

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059654A (en) * 1983-02-14 1991-10-22 Cuno Inc. Affinity matrices of modified polysaccharide supports
US4742046A (en) * 1984-08-03 1988-05-03 Medisearch S.A. Methods and compositions for inhibiting the infectious activity of viruses
JPS61165334A (ja) * 1984-08-03 1986-07-26 メデイサ−チ、エス、ア− ウイルスの感染活性の抑制方法および組成物
US4668621A (en) * 1985-04-22 1987-05-26 Wake Forest University Detecting blood clotting factors with immobilized fibrinogen and labeled fibrinogen
US5066480A (en) * 1988-04-11 1991-11-19 E. R. Squibb & Sons, Inc. Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
JPH06508823A (ja) * 1991-03-11 1994-10-06 ニュー　イングランド　メディカル　センター　ホスピタルズ，インコーポレイテッド ２，６シアル酸成分を含むインヒビターによるｐａｄｇｅｍ媒介相互作用の阻害方法
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide

Also Published As

Publication number Publication date
EP0631501B1 (en) 2000-08-30
AU681074B2 (en) 1997-08-21
EP0631501A4 (en) 1995-12-27
CA2132518A1 (en) 1993-09-30
EP0631501A1 (en) 1995-01-04
ATE195873T1 (de) 2000-09-15
DE69329333D1 (de) 2000-10-05
JPH07507769A (ja) 1995-08-31
US20030207796A1 (en) 2003-11-06
US5798332A (en) 1998-08-25
IL105064A0 (en) 1993-07-08
AU3917793A (en) 1993-10-21
US6117836A (en) 2000-09-12
WO1993018782A1 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
Gottlieb et al. Isolation of a clone of Chinese hamster ovary cells deficient in plant lectin-binding sites
Baenziger et al. Structure of the carbohydrate units of IgE immunoglobulin: II. Sequence of the sialic acid-containing glycopeptides
Kraemer Heparin releases heparan sulfate from the cell surface
Mellis et al. Structures of the O-glycosidically linked oligosaccharides of human IgD.
Platt et al. Proteoglycan metabolism associated with mouse metanephric development: morphologic and biochemical effects of β-D-xyloside
IL105064A (en) METHOD TO INHIBIT THE CONVERSION OF HUMAN FACTOR X TO HUMAN FACTOR Xa BY MEANS OF A REAGENT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID REAGENT
Miyachi et al. Syntheses of chondroitin sulfate tetrasaccharide structures containing 4, 6-disulfate patterns and analysis of their interaction with glycosaminoglycan-binding protein
Habuchi et al. Sulfation of sialyl lactosamine oligosaccharides by chondroitin 6-sulfotransferase
AU4469197A (en) Pharmaceutical compositions with antimicrobial activity
AU683090B2 (en) Aqueous polymer preparations
UA32522C2 (uk) Ліофілізована протипухлинна композиція і стерильна водна композиція для ін'єкцій на її основі
NZ236748A (en) Compositions for culturing and freezing cells or tissues containing hyaluronic acid in a concentration effective as a substitute for serum or serum products
ATE41785T1 (de) Membranoese polysaccharide, verwendbar insbesondere als arzneimittel und verfahren zu ihrer herstellung.
EP0642507A4 (en) Catalytic antibodies against cocaine and methods of using and producing same.
Chandrasekhar et al. The mode of action of the Laki-Lorand factor in the clotting of fibrinogen
Cöster et al. The co-polymeric structure of pig skin dermatan sulphate. Distribution of L-iduronic acid sulphate residues in co-polymeric chains
GB9711443D0 (en) Chemical suppositions
WO2002072059A3 (en) Topical composition comprising a functionally alkylating cosmetic bonding agent
Kelm et al. Reconstitution of the masking effect of sialic acid groups on sialidase-treated erythrocytes by the action of sialyltransferases
Van Holst et al. Hydroxyproline glycosides in secretory arabinogalactan-protein of Phaseolus vulgaris L.
Moretti et al. Vitamin A and mucopolysaccharide biosynthesis in colon homogenates
Kolset Synthesis and release of chondroitin sulphate and heparan sulphate proteoglycans from mouse macrophages in vitro
Ronin et al. Enzymatic transfer of oligosaccharide from oligosaccharide-lipids to an Asn-Ala-Thr containing heptapeptide
ZA931723B (en) Method for producing carbohydrates
Gottschalk The significance of neuraminic acid, serine and threonine for a glycoprotein inhibiting influenza virus haemagglutination

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
RH1 Patent not in force